The complement 3a receptor (C3aR1) participates in microglial signaling under pathological conditions and was recently shown to be activated by the neuropeptide TLQP-21. We previously demonstrated that TLQP-21 elicits hyperalgesia and contributes to nerve injury-induced hypersensitivity through an unknown mechanism in the spinal cord. Here we determined that this mechanism requires C3aR1 and that microglia are the cellular target for TLQP-21. We propose a novel neuroimmune signaling pathway involving TLQP-21-induced activation of microglial C3aR1 that then contributes to spinal neuroplasticity and neuropathic pain. This unique dual-ligand activation of C3aR1 by a neuropeptide (TLQP-21) and an immune mediator (C3a) represents a potential broad-spectrum mechanism throughout the CNS for integration of neuroimmune crosstalk at the molecular level.
| I N TR ODU C TI ON
The complement 3a receptor (C3aR1) was originally identified as the cognate G-protein coupled receptor for complement component 3a (C3a). C3aR1 was recently shown to also bind the neuropeptide TLQP-21 (Cero et al., 2014; Hannedouche et al., 2013) . TLQP-21 is generated from the neurotrophin-inducible protein VGF (nonacronymic), which has been implicated in neuroplasticity associated with learning and memory, depression, and chronic pain (Bartolomucci et al., 2006; Hunsberger et al., 2007; La Croix-Fralish, Austin, Zheng, Levitin, & Mogil, 2011; Lin et al., 2015; Moss et al., 2008; Riedl et al., 2009; Thakker-Varia et al., 2007) . TLQP-21 and C3a have a competitive relationship at the same binding site within C3aR1 (Cero et al., 2014; Hannedouche et al., 2013) .
Microglial signaling is a crucial factor in the response of the central nervous system (CNS) to injury and disease. In the dorsal horn, microglia mediate neuroinflammation in chronic pain states such as neuropathic pain (Ji, Xu, & Gao, 2014; Taves, Berta, Chen, & Ji, 2013) . C3aR1 participates in microglial signaling under pathological conditions including neurodegeneration and virus-induced cognitive impairment (Lian et al., 2016; Vasek et al., 2016) . Although the complement system has been implicated in mechanisms of neuropathic pain (Griffin et al., 2007; Liu et al., 1995; Twining et al., 2005) , the potential relevance of microglial C3aR1 in dorsal horn has not been addressed. We developed a simple and powerful new application of wide-field Ca 21 imaging to monitor C3aR1-mediated microglial activity in spinal cord slices from mice that express eGFP under the control of the Iba1 promoter.
TLQP-21 modulates nociceptive signaling and nerve injuryinduced hypersensitivity through both peripheral and spinal mechanisms Fairbanks et al., 2014; Rizzi et al., 2008) . We previously demonstrated that TLQP-21 elicits hyperalgesia and *Co-first author † Co-senior author participates in nerve injury-induced hypersensitivity through an unknown mechanism in the spinal cord (Fairbanks et al., 2014) . In the present study, we addressed the hypothesis that microglial C3aR1 is central to this mechanism.
| M A TE RI A L S A ND M E TH ODS

| Animals
All work with animals adhered to the guidelines of the Committee for
Research and Ethical Issues of the International Association for the Study of Pain and was approved by the Institutional Animal Care and Use Committee at the University of Minnesota (UofM) and/or University of Kentucky (UK) in accordance with American Veterinary Medical Association guidelines. ICR/CD-1 outbred mice were purchased from Envigo (Indianapolis, USA). C57/Bl6 mice were purchased from Charles-River (Indianapolis, USA). Iba1-eGFP, generated on a C57/Bl6 background, were provided by Dr. Kohsaka, National Institute of Neuroscience, Tokyo, Japan (Hirasawa et al., 2005) . Colonies were first established at the UofM, and then breeders were sent to UK.
Heterozygous mice were used for all experiments. C3aR1 knock-out mice on a Balb/cJ background and wild-type Balb/cJ were obtained from Jackson Labs (# 005712).
| In vivo pharmacological treatments
TLQP-21 (name derived from the four amino acids at the N-terminus of the peptide and the number of amino acids) and TLQP-R21A were obtained from Aapptec (Louisville, KY). The peptides were administered to the intrathecal (i.t.) space in awake male ICR/CD-1 (20-25 g, Envigo)
by direct lumbar puncture, as described previously (Fairbanks, 2003; Hylden & Wilcox, 1981) . The C3aR1 antagonist SB290157 (Cayman Chemical, Ann Arbor, MI) was dissolved in DMSO and then diluted to a final concentration of 5% DMSO (highest dose) or less (serial dilutions for lower doses) with 0.9% normal saline, pH 7.2. SB290157 was administered (i.t.) 5 min prior to TLQP-21 (i.t.) (Fairbanks et al., 2014) followed by heat hyperalgesia testing ( Figure 2a) ; in nerve-injured mice the antagonist was injected i.t. after measurement of predrug mechanical thresholds ( Figure 2c ). 
| Heat hyperalgesia testing
| Spared nerve injury (SNI) model
The spared nerve injury model is a well-established model that produces substantial and prolonged changes in mechanical sensitivity and cold responsiveness that closely mimic the cutaneous hypersensitivity associated with clinical neuropathic pain (Decosterd & Woolf, 2000) . SNI or sham surgery were performed under isoflurane anesthesia as described (Bourquin et al., 2006) . For RNA analysis and immunohistochemistry, SNI was performed at 35 days of age. For calcium imaging, we performed SNI at a younger age (25 days). SNI performed at this age yields both tactile hypersensitivity and spinal cord slices that are compatible with Fura-2 AM loading and calcium imaging (Doolen, Blake, Smith, & Taylor, 2012) . For calcium imaging and qPCR, mice were sacrificed at 2 weeks post-SNI, and fresh tissue was collected for either slice preparation or RNA extraction. To assess the time course of C3aR1 expression, mice were sacrificed by transcardial perfusion at 3, 14, and 28 days post-SNI.
| Mechanical threshold testing
Mice were acclimated at least 30 min in the testing environment within a plastic box on a raised metal mesh platform. .0 g were utilized. These were applied perpendicular to the ventralmedial hindpaw surface with sufficient force to cause a slight bending of the filament. A rapid withdrawal of the paw away from the stimulus fiber within 4 s was deemed as a positive response. Using an up-down statistical method (Chaplan, Bach, Pogrel, Chung, & Yaksh, 1994) , the 50% withdrawal threshold was calculated for each mouse and then averaged within the experimental groups. Mechanical hypersensitivity was confirmed in all SNI mice used in this study. 
| Primary microglial cultures
Cortical cells were collected from postnatal day 1-3 mouse pups of both sexes (CD-1, Charles River; Balb c/J wild-type or C3aR1 knockout, Jackson Laboratory) and plated under conditions that promote survival of glial cells but not neurons (Skaper, Argentini, & Barbierato, 2012) . Mixed glial cultures were maintained in EMEM 1 10% fetal Three to five coverslips were tested from three CD-1 WT, three C3aR1 WT, and three C3aR1 KO cultures. Cells were grouped into responders or nonresponders in a contingency table for each treatment and were compared using Fisher's exact test.
| Immunohistochemistry
Mice were deeply anesthetized with isoflurane and perfused via the heart with calcium-free Tyrode's solution (in mM: 116 NaCl, 5.4 KCl,
4 7H 2 O, 1.4 NaH 2 PO 4 , 5.6 glucose, and 26 Na 2 HCO 3 ) followed by fixative (4% paraformaldehyde and 0.2% picric acid in 0.1M phosphate buffer, pH 6.9). Tissues were dissected, incubated in 10% sucrose overnight at 48C, and then cryostat-sectioned (14 mm) and thaw-mounted on to gelatin-coated slides. Sections were preabsorbed in blocking buffer (PBS containing 0.3% Triton-X 100, 1% BSA, 1% normal donkey serum) for 30 min, incubated in primary antibodies overnight at 48C, rinsed with PBS 3 3 10 min, incubated in secondary antisera (1:300, Jackson ImmunoResearch, West Grove, CA) for 1 h at room temperature, washed with PBS, and coverslipped using PBS/glycerol containing 0.1% p-phenylenediamine (Sigma). Primary antibodies included: rat anti-C3aR1 (1:100, Hycult Biotech), rabbit anti-Iba1 (1:1000; Wako Chemicals), goat anticollagen IV (1:2500, SouthernBiotech), mouse anti-GFAP (1:1000, Sigma), mouse anti-MAP2 (1:5000; Millipore), and rabbit anti-NeuN (1:1000, Cell Signaling). Images were collected with an Olympus FluoView1000 confocal imaging system. Adjustments of contrast and brightness were performed in Adobe Photoshop CS5; images from wild type and knockout mice were adjusted identically. For quantification of colocalization of Iba1 and GFP labeling in Iba1-eGFP mice, images of dorsal horn were collected as z-stacks (6 optical sections, 1 lm apart) and projected in Image J. Three nonadjacent sections of lumbar spinal cord were imaged for each subject (n 5 3). The projected images were thresholded above the level of background staining intensity, using the same threshold value for all Iba1 and GFP images, respectively. Stacks of corresponding Iba1 and GFP images were created in Image J. Cellular profiles, identified based on the presence of a soma-like structure with associated processes, were outlined and assessed for presence of Iba1 and GFP labeling. Labeled profiles were counted, and the average number
of double-labeled and single-labeled profiles per section was calculated for each subject. For quantitative image analysis of C3aR1-ir, single optical sections of C3aR1/Iba1/MAP2 triple-labeling were collected using constant image acquisition settings. Iba1 staining was used for unbiased selection of the focal plane. Analysis was performed in Image J. MAP2 labeling was used for reproducible outlining of a region of dorsal horn that included laminae I-III. To measure the area of C3aR1 labeling, the images were thresholded by a blinded experimenter. Analysis by three different blinded experimenters yielded reproducible results.
C3aR1 labeling was expressed as % thresholded area. Data from three nonadjacent L3/L4 sections were averaged from each spinal cord.
| Statistical analysis
Data are expressed as the mean 6 SEM, with p < .05 as significant. p values were determined using t-tests for two-group analysis, and 1-or 2-way ANOVA with repeated measures followed by pairwise comparisons using GraphPad Prism software (version 6; GraphPad Software, San Diego, CA). Proportions of profiles/cells were compared using Fisher's exact test. 
| C3aR1 mediates TLQP-21-induced heat hyperalgesia and contributes to nerve injury-induced hyperalgesia
Intrathecal administration of TLQP-21 induces a transient, prostaglandin-dependent heat hyperalgesia in the warm water tail immersion assay (Fairbanks et al., 2014) . To determine if this pronociceptive effect is mediated by C3aR1, the C3aR1 antagonist SB290157 was injected before TLQP-21. Intrathecal SB290157 had no behavioral effect when injected alone, but dose-dependently (0.1-1.0 nmol) inhib- We previously used an immunoneutralization approach to demonstrate that TLQP-21 is necessary for nerve injury-induced hypersensitivity (Fairbanks et al., 2014) . To determine whether C3aR1 signaling is necessary as well, we evaluated the effect of SB290157 in the SNI model of neuropathic pain. SB290157 (1 nmol, i.t.) reversed mechanical hypersensitivity as compared to vehicle (Figure 2c These data indicate that C3aR1 mediates TLQP-21 signaling in dorsal horn.
| Peripheral nerve injury increases the spinal expression of C3aR1
Next we tested the hypothesis that SNI increases the expression of axis elicits signaling in neurons, astrocytes, and/or microglial cell types.
We found that C3aR1-ir was extensively co-localized with Iba1-ir at all time points examined (14 days post-SNI shown in Figure 6a ). In contrast, C3aR1-ir did not co-localize with either the astrocyte marker We next tested if TLQP-21 activates Ca 21 responses in neurons. To do this, we directly compared the population of profiles responding to TLQP-21 with the population of profiles that exhibit a high (>10% above baseline) response to glutamate -a population that fires action potentials and are thus categorized as neurons (Doolen et al., 2012) . We superfused slices with TLQP-21 (1 lM, 90 s), and then with glutamate (1 mM, 10 s), and analyzed 161 profiles (collected from slices from 7 mice). Profiles were classified as TLQP-21 "responders" if they exhibited increases in Ca 21 greater than 3% of baseline (noise accounts for roughly 3% change in baseline). The representative traces shown in Figure 7d- Spinal cord slices were superfused with TLQP-21 (1 lM, 90 s), and then with glutamate (1 mM, 10 s). Profiles were classified as TLQP-21 'responders' if they exhibited increases in Ca 21 greater than 3% of baseline (noise accounts for roughly 3% change in baseline). Both responders and nonresponders were further categorized based on whether they exhibited no (<3% baseline), low (3-10% baseline), or high (>10% baseline) Ca 21 signals in response to glutamate. respectively; p < .001). These data illustrate that TLQP-21 responsive cells typically do not exhibit a high response to glutamate that is characteristic of neurons. These findings suggest that the majority of TLQP-21-responsive profiles belong to a cell population that is largely distinct from the predominantly neuronal population.
Having largely ruled out a contribution of astrocytes or neurons, we next tested the hypothesis that TLQP-21-evoked Ca 21 transients occur in microglia. The selectivity of available microglial inhibitors has been widely questioned (Liu, Zhang, Zhu, Luo, & Liu, 2015; Moller et al., 2016; Peng, Ma, Lv, Hu, & Liu, 2016) ; therefore, we employed mice that express eGFP under the control of the Iba1 promoter (Iba1-eGFP mice). We first characterized these mice with double-label immunohistochemistry of eGFP and Iba1-ir in dorsal horn sections GFP-negative: 59% high, 39% low; p < .0001, Fisher's exact test).
These data suggest that the eGFP-negative population overlaps with a population of glutamate responsive cells that we consider to be neurons (Doolen et al., 2012 (Wang, Kim, van Breemen, & McLarnon, 2000) . Cells were considered responsive to ATP or TLQP-21 if the peak amplitude was twofold greater than noise. We found that all TLQP-21-responsive cells were ATPresponsive (representative trace shown in Figure 8a 
| D I SCUSSION
C3aR1 has emerged as a neuro-glial mediator that contributes critically to pathological processes in the CNS by regulating neuroinflammation as well as neuronal structure and function (Lian et al., 2015; Vasek et al., 2016) . We previously demonstrated that the newly identified ligand of C3aR1, TLQP-21, elicits hyperalgesia and participates in the development and maintenance of nerve injury-induced hypersensitivity (Fairbanks et al., 2014) . Here we examined the interaction of TLQP-21
and C3aR1, and provide the first evidence that microglial C3aR1 mediates the effects of TLQP-21 within the central nervous system.
| TLQP-21 activates spinal C3aR1
We show that TLQP-21 signaling in spinal cord is C3aR1-dependent. 
| High fidelity Ca 21 imaging in ex vivo microglia
Until recently, microglial Ca 21 signaling had only been characterized in cultured cells (Farber & Kettenmann, 2006) . Here we took advantage of eGFP expression under the control of the Iba1 promoter to perform real-time, wide-field Ca 21 imaging of microglial activity with high fidelity in a spinal cord slice preparation for the first time. We found that Fura-2 AM was taken up by 79% of Iba1-eGFP positive cells, accounting for a majority of microglia in the dorsal horn. This represents a powerful and novel approach to directly monitor microglia in an environment where they retain the ability to interact with other cell types, including neurons and astrocytes (Brawek & Garaschuk, 2013; Nimmerjahn, Kirchhoff, & Helmchen, 2005; Tsuda & Inoue, 2016 
| C3aR1 in nerve injury-induced spinal neuroplasticity
Using immunoneutralization, we previously demonstrated that endogenous spinal TLQP-21 contributes to the development and maintenance of nerve injury-induced hypersensitivity (Fairbanks et al., 2014) . The present results identify microglial C3aR1 as the pronociceptive target for TLQP-21. Since the TLQP-21 precursor VGF is upregulated in sensory neurons within 24 h of nerve injury (Riedl et al., 2009) , spinal TLQP-21 released from injured sensory neurons is positioned to function as an endogenous danger signal that contributes to spinal neuroinflammation after nerve injury through activation of C3aR1.
Little is known about the spinal availability of the originally characterized C3aR1 ligand C3a. Although expression of C3, the precursor of C3a, emerges in spinal microglia three days after peripheral nerve injury (Gattlen et al., 2016; Griffin et al., 2007; Liu et al., 1995; Twining et al., 2005) , the generation of C3a or its contribution to hypersensitivity remains to be established.
We found that SNI increased both microglial C3aR1 expression and TLQP-21-evoked C3aR1-dependent Ca 21 signaling in the dorsal horn of the spinal cord. Moreover, pharmacological inhibition of C3aR1 attenuated the behavioral hypersensitivity associated with SNI. These results provide the first evidence that microglial C3aR1 contributes to neuropathic pain.
C3aR1 activation of monocytes induces release of ATP and cytokines (Asgari et al., 2013) . Spinal microglia also have the capacity to release ATP (Liu, Kalous, Werry, & Bennett, 2006) , and microglial purinergic receptors are heavily implicated in neuropathic pain mechanisms (Beggs, Trang, & Salter, 2012) . This leads us to speculate that the potential downstream consequences of C3aR1 signaling following nerve injury include microglial release of ATP and cytokines, including mediators of spinal neuroplasticity such as IL-1b (Clark et al., 2015; Gruber-Schoffnegger et al., 2013) .
| C3aR1 is expressed in meningeal/subarachnoid monocytes
The present study makes the intriguing and novel observation that C3aR1 is expressed in meningeal/subarachnoid monocytes. It is well documented that monocytes can be found in mouse meninges and human cerebrospinal fluid, and that their number increases in pathological states such as multiple sclerosis (Chinnery, Ruitenberg, & McMenamin, 2010; Polfliet et al., 2001; Waschbisch et al., 2016) . Thus, we suggest that C3aR1 is well-positioned to respond to complement pathway activation within the cerebrospinal fluid (e.g., in response to pathogens). Importantly, VGF fragments have been detected in multiple proteomic studies of human CSF (Bartolomucci et al., 2011) . Therefore, we speculate that TLQP-21 acts at C3aR1 on monocytes in the CSF to promote neuroinflammation. Furthermore, since activated monocytes release prostaglandins that may diffuse within the spinal cord (Ulmann, Hirbec, & Rassendren, 2010) , C3aR1 receptors on CSF monocytes may provide insight into the mechanisms underlying the prostaglandinmediated thermal hyperalgesia observed following intrathecal injection of TLQP-21 (Fairbanks et al., 2014) .
In summary, we show that the spinal mechanisms of pronociceptive actions of TLQP-21 involve direct activation of C3aR1 on microglia. This study provides the first evidence that microglial C3aR1 contributes to maladaptive changes after neuropathic injury, raising the possibility that C3aR1 may be a novel therapeutic target for the control of chronic pain. Our results are also the first to describe a receptor within the CNS that is activated by both a neuropeptide and an immune mediator (C3a). The identification of C3aR1 as the spinal target of TLQP-21 suggests a novel interplay of neuronal and immune signaling mediators in CNS diseases.
